Plasma alpha‐synuclein detected by single molecule array is increased in PD
Open accessAbstract
We utilized ultrasensitive single molecule technology to measure plasma alpha‐synuclein in 221 subjects (51 controls, 170 PD ). Plasma alpha‐synuclein levels were significantly higher in PD than controls (15506.3 vs. 13057.0 pg/mL, P = 0.037), adjusting for age and gender. In PD , alpha‐synuclein levels did not vary by H&Y stage or UPDRS motor scores but were significantly higher in PD patients with poorer cognition ( MMSE ≤ 25) than controls ( P = 0.016, Bonferroni corrected P = 0.047). Alpha‐synuclein levels quantified using ultrasensitive single molecule technology discriminate PD from controls and correlate with cognitive severity. These preliminary findings require independent validation to determine the utility of this assay.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Plasma α-synuclein level in PD is higher than in healthy controls, indicating possible reduction of protein degradation rate.
“Plasma α-synuclein level in PD is higher than that in healthy controls [121], indicating possible reduction of protein degradation rate.”
From Degradation of Tyrosine Hydroxylase by the Ubiquitin-Proteasome System in the Pathogenesis of Parkinson’s Disease and Dopa-Responsive Dystonia (2020) · cites this paper as [121]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107 · see citing works
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,412 · see citing works
Overdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,756 · see citing works
Stages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689 · see citing works
The Mini-Mental State Examination
Folstein, M. F. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790060110016 · Cited by 1,975 · see citing works
The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations
Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease (2003) · Movement Disorders · doi:10.1002/mds.10473 · Cited by 1,811 · see citing works
(1998) · Europe PMC (PubMed Central) · Cited by 1,594 · see citing works
Stebbins, G. T., Goetz, C. G., Burn, D. J., Jankovic, J. J., Khoo, T. K., & Tilley, B. C. (2013) · Movement Disorders · doi:10.1002/mds.25383 · Cited by 936 · see citing works
Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease
Shi, M., Liu, C., Cook, T. J., Bullock, K. M., Zhao, Y., Ginghina, C., Li, Y., Aro, P., Dator, R., He, C., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1314-y · Cited by 676 · see citing works
Li, W., West, N. C., Colla, E., Pletniková, O., Troncoso, J. C., Marsh, L., Dawson, T. M., Jäkälä, P., Hartmann, T., Price, D. L., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406976102 · Cited by 473 · see citing works
Wilson, D. H., Rissin, D. M., Kan, C. W., Fournier, D. R., Piech, T., Campbell, T. G., Meyer, R. E., Fishburn, M. W., Cabrera, C., Patel, P. P., et al. (2015) · SLAS TECHNOLOGY · doi:10.1177/2211068215589580 · Cited by 470 · see citing works
Therapeutic approaches to target alpha-synuclein pathology
Brundin, P., Dave, K. D., & Kordower, J. H. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.10.003 · Cited by 244 · see citing works
APOE,MAPT, andSNCAGenes and Cognitive Performance in Parkinson Disease
Mata, I. F., Leverenz, J. B., Weintraub, D. A., Trojanowski, J. Q., Hurtig, H. I., Deerlin, V. M. V., Ritz, B. R., Rausch, R., Rhodes, S. L., Factor, S. A., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1455 · Cited by 203 · see citing works
Plasma α-synuclein is decreased in subjects with Parkinson's disease
Li, Q., Mok, S. S., Laughton, K. M., McLean, C., Cappai, R., Masters, C. L., Culvenor, J. G., & Horne, M. K. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.12.006 · Cited by 160 · see citing works
Plasma α-synuclein predicts cognitive decline in Parkinson’s disease
Lin, C., Yang, S., Horng, H. E., Yang, C., Chieh, J.-J., Chen, H.-H., Liu, B.-H., & Chiu, M. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-314857 · Cited by 154 · see citing works
Blood-based biomarkers for Parkinson's disease
Chahine, L. M., Stern, M. B., & Chen‐Plotkin, A. S. (2013) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(13)70025-7 · Cited by 151 · see citing works
Wang, X., Yu, S., Li, F., & Feng, T. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.05.030 · Cited by 148 · see citing works
Plasma α‐synuclein in patients with Parkinson's disease with and without treatment
Durán, R., Barrero, F. J., Morales, B., Luna, J. D. D., Ramírez, M. R., & Vives, F. (2010) · Movement Disorders · doi:10.1002/mds.22928 · Cited by 111 · see citing works
α-Synuclein Levels in Blood Plasma from LRRK2 Mutation Carriers
Gorostidi, A., Bergareche, A., Ruiz‐Martínez, J., Martí-Massó, J. F., Rodríguez‐Oroz, M., Varghese, S., Qureshi, M. M., Alzahmi, F., Al‐Hayani, A., de Munaín, A. L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052312 · Cited by 46 · see citing works
The relation between plasma α-synuclein level and clinical symptoms or signs of Parkinson's disease
Malec‐Litwinowicz, M., Plewka, A., Plewka, D., Bogunia, E., Morek, M., Szczudlik, A., Szubiga, M., & Rudzińska, M. (2017) · Neurologia i Neurochirurgia Polska · doi:10.1016/j.pjnns.2017.11.009 · Cited by 41 · see citing works
A Multi-site In-depth Evaluation of the Quanterix Simoa from a User’s Perspective
Chunyk, A. G., Joyce, A. P., Fischer, S. K., et al. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0156-7 · Cited by 20 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Kawahata, I., & Fukunaga, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113779 · Cited by 71 · see citing works
Biosensing strategies for amyloid‐like protein aggregates
Zhou, Y., Yan, S., Dong, W., Wu, C., Zhao, Z., Wang, R., Duo, Y., Huang, Y., Xu, D., & Jiang, C. (2024) · BMEMat · doi:10.1002/bmm2.12053 · Cited by 16 · see citing works
- Authors
- Ng, A. S. L., Tan, Y. J., Lu, Z., Ng, E. Y. L., Ng, S. Y. E., Chia, N. S. Y., Setiawan, F., Xu, Z., Tay, K. Y., Prakash, K. M., Au, W. L., Tan, E., & Tan, L. C. S.
- Affiliations
- Tan Tock Seng Hospital (SG)
- Singapore General Hospital (SG)
- National University of Singapore (SG)
- Corresponding author
- Ng, Adeline S. L.
- Tan, Louis C. S.
- ORCID
- Venue
- Annals of Clinical and Translational Neurology
- Publisher
- Wiley
- Published
- 2019-02-15
- Volume
- 6
- Issue
- 3
- Pages
- 615-619
- ISSN
- 2328-9503 (ISSN-L)
- PMC
- PMC6414476
- OpenAlex
- W2912497832
- Cited by
- 53
- References
- 21
- Citations by year
- 2026: 2 · 2025: 11 · 2024: 6 · 2023: 8 · 2022: 9 · 2021: 5 · 2020: 9 · 2019: 3
- FWCI
- 4.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Annals of Clinical and Translational Neurology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- National University of Singapore (submittedVersion)
- Funders
- Singapore's National Medical Research Council
- Clinician-Scientist New Investigator Grant (CIRG/1416/2015)
- Singapore Translational Research (NMRC/STaR/014/2013)
- Parkinson's disease Translational and Clinical Research (TCR12dec010)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Neurology › Neurological disorders and treatments
- Keywords
- alpha-synuclein, plasma biomarkers, Parkinson's disease, single molecule array, cognitive impairment, disease severity, diagnostic biomarkers, ultrasensitive immunoassay
- MeSH terms
- Single Molecule Imaging, Aged, Female, Humans, Male, Middle Aged, Parkinson Disease, Plasma, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
